Cristina Lorente-Martin

Barcelona, CT, Spain

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications

Long-Term Outcomes in Patients With Recurrent Ovarian Cancer and Exceptional Response to PARP Inhibitors.

Long-Term Outcomes in Patients With Recurrent Ovarian Cancer and Exceptional Response to PARP Inhibitors.

Journal: JAMA oncology
Published: June 25, 2026

An ambispective, real-world multi-center study of DOstarlimab in patients with Recurrent or Advanced DNA mismatch repair deficient/microsatellite instability-high endometrial cancer (GEICO 120-R/DORA study).

An ambispective, real-world multi-center study of DOstarlimab in patients with Recurrent or Advanced DNA mismatch repair deficient/microsatellite instability-high endometrial cancer (GEICO 120-R/DORA study).

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Published: February 10, 2025

SEOM-GEICO clinical guideline on epithelial ovarian cancer (2023).

SEOM-GEICO clinical guideline on epithelial ovarian cancer (2023).

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
Published: May 17, 2024

Homologous Recombination Repair Gene Mutations to Predict Olaparib Plus Bevacizumab Efficacy in the First-Line Ovarian Cancer PAOLA-1/ENGOT-ov25 Trial.

Homologous Recombination Repair Gene Mutations to Predict Olaparib Plus Bevacizumab Efficacy in the First-Line Ovarian Cancer PAOLA-1/ENGOT-ov25 Trial.

Journal: JCO precision oncology
Published: January 30, 2023

Nano-Based Approved Pharmaceuticals for Cancer Treatment: Present and Future Challenges.

Nano-Based Approved Pharmaceuticals for Cancer Treatment: Present and Future Challenges.

Journal: Biomolecules
Published: May 10, 2022

Association of location of BRCA1 and BRCA2 mutations with benefit from olaparib and bevacizumab maintenance in high-grade ovarian cancer: phase III PAOLA-1/ENGOT-ov25 trial subgroup exploratory analysis.

Association of location of BRCA1 and BRCA2 mutations with benefit from olaparib and bevacizumab maintenance in high-grade ovarian cancer: phase III PAOLA-1/ENGOT-ov25 trial subgroup exploratory analysis.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: April 19, 2022

The impact of olaparib dose reduction and treatment interruption on treatment outcome in the SOLO2/ENGOT-ov21 platinum-sensitive recurrent ovarian cancer.

The impact of olaparib dose reduction and treatment interruption on treatment outcome in the SOLO2/ENGOT-ov21 platinum-sensitive recurrent ovarian cancer.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: November 09, 2021

SEOM clinical guideline in ovarian cancer (2020).

SEOM clinical guideline in ovarian cancer (2020).

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
Published: December 16, 2020

Management of advanced ovarian cancer in Spain: an expert Delphi consensus.

Management of advanced ovarian cancer in Spain: an expert Delphi consensus.

Journal: Journal of ovarian research
Published: November 17, 2020
Showing 1-9 of 9

Last Updated: 09/26/2026